What it does is support the metabolic conditions insulin sensitivity, muscle function, mood, bone health that make weight loss more effective and sustainable when combined with a caloric deficit, adequate protein, resistance training, and (when appropriate) GLP-1 therapy
however, it is greatly applicable in cancer treatment [286]
All three major weekly GLP-class agents sit in a similar half-life band, which is why all three use the same weekly injection schedule: No head-to-head pharmacokinetic trial has directly compared these three compounds
Beyond serving as energetic substrates, SCFAs exert important endocrine functions by binding to G-proteincoupled receptors, namely FFAR2 (GPR43) and FFAR3 (GPR41), expressed on enteroendocrine L cells and other cell types across rodents and humans (59, 60)
BizinoMBJazetIMde HeerPvan EykHJDekkersIARensenPCNet alPlacebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation